FEBUXOSTAT | N021856 | TAKEDA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2019-04-26 | Terminated 2019-10-09 | — | |
| D. Del. | 2018-07-02 | Terminated 2018-11-20 | — | |
| D. Del. | 2018-06-14 | Terminated 2018-11-20 | — | |
| D. Del. | 2017-09-15 | Terminated 2018-04-20 | — | |
| D. Del. | 2017-06-23 | Terminated 2017-11-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Public Citizen FDA-2018-P-2408 · 22 docket documents Public Citizen filed this citizen petition on June 21, 2018, under Section 355(e) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA immediately remove from the market all medications containing febuxostat (marketed as Uloric), a xanthine oxidase inhibitor used to treat gout, becaus | Other | 2018-06-21 | Denied | Public Citizen |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$10.55
per ea
Lowest NADAC/Unit
$10.53
per ea
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 64764091830ULORIC 40 MG TABLET | $10.55 | EA | Brand | $0.2128 | 2026-06-17 |
| 64764067730ULORIC 80 MG TABLET | $10.53 | EA | Brand | $0.3297 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.